IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

 IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, announced

 IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the “Company“, “IMCannabis“, or “IMC“), a leading medical cannabis company with operations in Israel and Germany, announced today that the Company received written notification (the “Notification Letter“) from The Nasdaq Stock Market LLC (“Nasdaq“) on August 1, 2023, that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on Nasdaq.

Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common shares for the 30 consecutive business days from June 16, 2023 to July 31, 2023, the Company no longer meets the minimum bid price requirement.

The Notification Letter does not impact the Company’s listing on the Nasdaq at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until January 29, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s common shares must have a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by January 29, 2024, the Company may be eligible for additional time to regain compliance or may face delisting.

The Company’s common shares are also listed on the Canadian Securities Exchange and the Notification Letter does not affect the Company’s compliance status with such listing.

Total
0
Shares
Related Posts
Read More

CBD Of Denver’s Success In Challenging Climate With Increase In Q4 Revenue

CBD of Denver has reported strong fourth-quarter revenues of approximately $1.31m, with $1.13m generated by Luxora and $176,000 by Libra 9. The CBD company attributed its growth to a number of factors, including its partnership with EDEKA and the popularity of its Magic Lappen product, both of which increased sales across Germany. CBD of Denver also highlighted the success of Libra 9's attendance at trade shows, which boosted brand recognition and allowed the company to form several significant partnerships. Meanwhile, Luxora's expansion into the European CBD wholesale market was credited with contributing significantly to the company's growth. Following the German government's expected approval of relevant legislation, Luxora Solutions will expand further into the German market. Germany's decision on legalising marijuana, which was set to be made in December, has been delayed until next year.

CBDD